Aclaris Therapeutics, Inc. (FRA:8AT)

Aclaris Therapeutics Statistics

Total Valuation

FRA:8AT has a market cap or net worth of EUR 243.25 million. The enterprise value is 101.35 million.

Market Cap	243.25M
Enterprise Value	101.35M

Important Dates

The next estimated earnings date is Monday, February 23, 2026.

Earnings Date	Feb 23, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	108.35M
Shares Outstanding	n/a
Shares Change (YoY)	+62.68%
Shares Change (QoQ)	+0.03%
Owned by Insiders (%)	2.69%
Owned by Institutions (%)	58.77%
Float	82.29M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	18.13
PB Ratio	2.38
P/TBV Ratio	2.38
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-0.84
EV / Sales	7.48
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.76

Financial Position

The company has a current ratio of 3.92, with a Debt / Equity ratio of 0.02.

Current Ratio	3.92
Quick Ratio	3.92
Debt / Equity	0.02
Debt / EBITDA	n/a
Debt / FCF	-0.05
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -113.23% and return on invested capital (ROIC) is -32.23%.

Return on Equity (ROE)	-113.23%
Return on Assets (ROA)	-22.98%
Return on Invested Capital (ROIC)	-32.23%
Return on Capital Employed (ROCE)	-43.90%
Revenue Per Employee	212,967
Profits Per Employee	-1.92M
Employee Count	64
Asset Turnover	0.09
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -30.78% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-30.78%
50-Day Moving Average	1.89
200-Day Moving Average	1.51
Relative Strength Index (RSI)	60.97
Average Volume (20 Days)	376

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.16

Income Statement

In the last 12 months, FRA:8AT had revenue of EUR 13.42 million and -120.75 million in losses. Loss per share was -1.04.

Revenue	13.42M
Gross Profit	-28.09M
Operating Income	-56.09M
Pretax Income	-120.75M
Net Income	-120.75M
EBITDA	-56.03M
EBIT	-56.09M
Loss Per Share	-1.04

Balance Sheet

The company has 81.75 million in cash and 1.91 million in debt, giving a net cash position of 140.60 million.

Cash & Cash Equivalents	81.75M
Total Debt	1.91M
Net Cash	140.60M
Net Cash Per Share	n/a
Equity (Book Value)	102.36M
Book Value Per Share	0.94
Working Capital	63.89M

Cash Flow

In the last 12 months, operating cash flow was -36.58 million and capital expenditures -74,150, giving a free cash flow of -36.65 million.

Operating Cash Flow	-36.58M
Capital Expenditures	-74,150
Free Cash Flow	-36.65M
FCF Per Share	n/a

Margins

Gross Margin	-209.38%
Operating Margin	-418.06%
Pretax Margin	-900.01%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

FRA:8AT does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-62.68%
Shareholder Yield	-62.68%
Earnings Yield	-49.64%
FCF Yield	-15.07%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:8AT has an Altman Z-Score of -6.04 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-6.04
Piotroski F-Score	1